EUVIMEDEUVIMED entdecken
Open Access

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

Carrie Ho, Ajay K Gopal, Brian G Till, Mazyar Shadman, Ryan C Lynch, Andrew J Cowan, Qian V Wu, Jenna Voutsinas, Heather A Rasmussen, Katherine Blue, Chaitra S Ujjani, Ryan D Cassaday und 3 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.10.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Carrie Ho und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lymphoma, Large B-Cell, Diffuse, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While generally ineffective in relapsed diffuse large B cell lymphoma (DLBCL), immune checkpoint inhibitors (ICIs) may hold greater promise in untreated, immunocompetent patients. We previously reported safety and early efficacy of pembrolizumab plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (PR-CHOP) in a phase I trial of untreated DLBCL, noting responses in 90% of patients (complete response 77%) and a 2-year progression-free survival (PFS) of 83%. We herein report long-term safety and efficacy at 5-year follow up. PATIENTS AND METHODS: Adult patients with untreated DLBCL or grade 3b follicular lymphoma, intended to receive 6 cycles of R-CHOP were eligible. Patients (N = 30) were treated with pembrolizumab 200 mg IV and R-CHOP in 21-day cycles for 6 cycles. RESULTS: At median follow up of 4.8 years, 5-year PFS was 71% (CI, 54%-94%) and 5-year overall survival was 83% (CI, 71%-98%). Immune-related adverse events (IRAEs) occurred in 7 (23%) patients (10% grade 3/4). Three IRAEs (rash, thyroiditis, rheumatoid arthritis) occurred beyond 3 months of treatment completion. PD-L1 tumor expression was documented in 19 of 23 (83%) tested patients. None of the 19 patients who had any PD-L1 expression have relapsed, whereas 2 out of the 4 patients with no PD-L1 expression have relapsed. CONCLUSION: PR-CHOP has led to durable responses in most patients, with the best outcomes in PD-L1-expressing disease. Furthermore, the safety profile was manageable, with no consistent pattern of late events. These data support ongoing strategies incorporating ICIs in frontline DLBCL therapy and confirmation of predictive biomarkers including tumor PD-L1 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, HumanizedAdultHumansRituximabVincristinePrednisoneFollow-Up StudiesAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

B-cell lymphomaImmune checkpoint inhibitorsImmunotherapyNon-Hodgkin lymphomaPD-L1

Substanzen

RituximabVincristinePrednisonepembrolizumabB7-H1 AntigenAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: carrho@uw.edu.
  • Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA.
  • Department of Laboratory Medicine, Division of Hematopathology, University of Washington, Seattle, WA.

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • National Cancer Institute
  • Merck Sharp and Dohme United Kingdom
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Ho, C., Gopal, A. K., Till, B. G., Shadman, M., Lynch, R. C., Cowan, A. J., Wu, Q. V., Voutsinas, J., Rasmussen, H. A., Blue, K., Ujjani, C. S., Cassaday, R. D., Fromm, J. R., Fang, M., & Smith, S. D. (2024). Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.10.002

Vancouver

Ho C, Gopal AK, Till BG, Shadman M, Lynch RC, Cowan AJ, et al. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.10.002

BibTeX
@article{Ho2024,
  author = {Ho, Carrie and Gopal, Ajay K and Till, Brian G and Shadman, Mazyar and Lynch, Ryan C and Cowan, Andrew J and Wu, Qian V and Voutsinas, Jenna and Rasmussen, Heather A and Blue, Katherine and Ujjani, Chaitra S and Cassaday, Ryan D and Fromm, Jonathan R and Fang, Min and Smith, Stephen D},
  title = {Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.10.002}
}
Kostenlos starten →